2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Iron Supplementation for the Treatment of Restless Legs Syndrome – A Systematic Review and Meta-Analysis

M. Kestenbaum, N. Lev (Kfar Saba, Israel)

Restless Leg Syndrome, RBD and Other Sleep Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Is Restless Legs Syndrome Usual in Patients with Sickle Cell Disease and Beta Thalassemia?

E. Okuyucu, M. Guntel, E. Ucar, G. Oktay (Hatay, Turkey)

Restless Leg Syndrome, RBD and Other Sleep Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Is sprint running exercise feasible, safe and enjoyable to subjects with mild-to-moderate Parkinson’s disease?

E. Monteiro, L. Peyré-Tartaruga, E. da Silva, A. Zanardi, P. Jimenez-Reyes, J. Morin, A. Pagnussat (Porto Alegre, Brazil)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Is the activation ratio of transversus abdominis associated with mobility and core endurance in patients with Idiopathic Parkinson’s Disease?: A Preliminary study

B. Aktar, S. Ozyurek, E. Goz, B. Donmez Colakoglu, B. Balci (Izmir, Turkey)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Is the gene expression of TAF1 modified by the X-linked dystonia-parkinsonism-associated hexanucleotide repeat?

K. Grütz, S. Schaake, B. Laabs, CJ. Reyes, U. Walter, D. Dressler, RD. Jamora, RL. Rosales, N. Brüggemann, K. Lohmann, IR. König, C. Klein, A. Westenberger (Lübeck, Germany)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Isolated delusion in idiopathic Parkinson’s disease: particularities in a subgroup of patients

A. Gonçalves, A. Delgado, J. Velosa, R. Simões, J. Vale (Loures, Portugal)

Psychiatric Manifestations  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Isolated unilateral tensor veli palatini myoclonus causing objective tinnitus without palatal elevation

C. Selvadurai, S. Schaefer (New Haven, CT, USA)

Myoclonus  ·  Les Muses, Level 3

1:45pm-3:15pm

Kinematic Gait Analysis in patients with ataxic disorders

D. Batra, A. Bhattacharya, A. Stezin, N. Kamble, P. Pal (Bengaluru, India)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Laboratory Performance of the DopaFuse® Delivery System

R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site

M. Facheris, X. Qi, C. Locke, M. Rosebraugh, J. Benesh (North Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3